Stable angina pectoris is a common disorder; its prevalence increases with age. Patients with stable angina pectoris experience a pressure or a choking sensation in the chest and adjacent areas or shortness of breath (angina equivalent) associated with physical or emotional stress. Most patients with stable angina pectoris have severe obstructive atherosclerotic lesions of complex morphology in one or more coronary arteries and multiple non-obstructive lesions. Obstructive lesions limit the increase of blood flow that is required during periods of increased myocardial oxygen demand, such as exercise.

The endothelium overlying the lesions is dysfunctional and is responsible for paradoxical constriction of the stenotic site during exercise, resulting in further reduction of blood flow distal to the lesion. The resultant imbalance between myocardial oxygen supply and demand produces reversible myocardial ischaemia and its clinical consequences, such as anginal pain and/or shortness of breath. Non-obstructive lesions are lipid-rich and soft in consistency and the endothelium overlying these lesions is prone to fissuring and disruption. The exact mechanism of plaque-endothelial surface disruption remains elusive. Several mechanisms, including an active inflammatory process, have been implicated. The fissured endothelium exposes the atheromatous material inside the vessel wall to the circulating blood. This results in platelet aggregation and deposition, which may be followed by additional intraluminal thrombosis. The clinical presentation may remain silent or manifest as acute coronary syndrome (myocardial infarction (MI), unstable angina) or sudden ischaemic death.

The annual death rate of patients with stable angina is 1.6% to 3.2%. The most important determinant of prognosis is underlying left-ventricular systolic and diastolic pressure; and symptoms and myocardial ischaemia. Anti-anginal drugs (long-acting nitrates, beta-blockers and calcium channel blockers) and revascularisation procedures alleviate or prevent anginal symptoms but have not been shown to improve survival or reduce the incidence of MI in patients with stable angina pectoris. On the other hand, the strategies that reduce the incidence of adverse outcomes have little anti-anginal effect. Therefore, treatment of stable angina must include the use of anti-anginal drugs and/or revascularisation procedures plus strategies that reduce adverse clinical outcomes.

Currently available anti-anginal drugs (long-acting nitrates, beta-blockers and calcium channel blockers) are usually the first option. Revascularisation procedures, percutaneous balloon dilation of the coronary artery (PTCA), with or without stent placement, are being used increasingly, especially in the US, and coronary bypass surgery is now being offered only to selected patients with stable angina pectoris.
Drugs

Nitrates are nitric oxide donors and predominantly reduce myocardial oxygen demand by reducing venous return. These agents also dilate stenotic coronary lesions and increase sub-endocardial blood flow to the ischaemic areas. Sublingual nitroglycerin is very effective and prolongs exercise tolerance in patients with stable angina pectoris. Long-acting and sustained-release formulations of nitrates, although used widely, do not provide 24-hour anti-anginal prophylaxis due to development of tolerance. Based on the published data, it can be concluded that none of the nitrate preparations or regimens provide continuous 24-hour anti-anginal prophylaxis. Many patients are unable to tolerate intermittent therapy with nitrates due to nitrate-induced headaches.

Beta-blockers reduce myocardial oxygen demand by reducing heart rate, myocardial contractility and exercise-induced increase in systolic blood pressure. Beta-blockers also increase coronary blood flow by increasing the diastolic filling period. These agents are the most effective anti-ischaemic agents and reduce exercise and ambulatory ischaemia to a greater extent than other anti-anginal drugs. Both non-selective and cardio-selective agents have been shown to improve exercise performance and reduce exercise-induced ischaemia in patients with stable angina pectoris.

Beta-blockers improve survival and reduce hospitalisation in patients with reduced left-ventricular function. However, there are no studies of beta-blockers on survival in patients with stable angina pectoris and normal left-ventricular function. Some patients are unable to tolerate beta-blockers due to excessive decrease in heart rate or fatigue, or due to concomitant diseases such as severe chronic obstructive pulmonary disease, bronchial asthma and severe peripheral vascular disease with resting limb ischaemia.

Calcium channel blockers act mainly by vasodilating the coronary arteries and by reducing peripheral vascular resistance. Non-dihydropyridine agents, verapamil and diltiazem, depress sinoatrial and atrio-ventricular node activity and also reduce myocardial oxygen demand. Long-acting dihydropyridine agents that are widely used to treat patients with stable angina primarily reduce myocardial oxygen demand by their predominant arterial dilating effects.

Recent studies with long-acting dihydropyridine and non-dihydropyridine groups of calcium channel blockers have shown that these agents are relatively safe and effective in patients with stable angina and preserved left-ventricular function. Calcium channel blockers should be avoided in patients with stable angina who have systolic left-ventricular dysfunction.

When used in adequate doses, all three classes of anti-anginal drugs, i.e. long-acting nitrates, beta-blockers and calcium channel blockers, have been shown to increase angina-free walking duration and total exercise time and to reduce angina frequency during daily activities. The combination of two agents from different classes (beta-blocker plus a long-acting nitrate or a calcium channel blocker, especially a dihydropyridine agent) may be more effective than monotherapy. However, triple therapy is not necessarily superior to treatment with two agents of different classes.

None of the three classes of anti-anginal drugs has been shown to reduce the frequency of serious adverse outcomes in patients with stable angina, the exception being patients with stable angina who have experienced a recent MI or who have reduced left-ventricular function; beta-blockers improve survival in these patients.

Nicorandil is a nitro-vasodilator with potassium channel-opening properties. Improvement in exercise tolerance has been reported in some studies, but not all. On the other hand, in patients with coronary artery disease, nicorandil was shown to reduce the incidence of serious adverse outcomes compared with placebo.

The metabolic agents trimetazidine (available in some countries) and ranolazine (not available as yet) are effective anti-anginal and anti-ischaemic agents and hold promise as they are devoid of circulating and haemodynamic effects.

Devices and Coronary Bypass Surgery

Revascularisation procedures increase coronary blood flow and have no effect on myocardial oxygen demand. Several studies have shown that PTCA, with or without stent placement, relieves anginal episodes in the majority of patients and increases angina-free walking time. However, the restenosis rate (20% to 30%) and recurrence of symptoms has remained a major problem especially in patients with diabetes mellitus. Drug-coated stents (sirolimus-eluting stents, paclitaxel-eluting stents) have reduced the rates of restenosis significantly. However, acute thrombosis of the stent still remains an issue. The majority of patients who undergo balloon dilation of the coronary artery with or without stent placement are currently maintained on anti-anginal drug therapy.

Compared with medical therapy (anti-anginal drugs) percutaneous coronary interventions do not reduce mortality or the incidence of MI in patients with stable angina pectoris. In a randomised study, in
Q. How would your patient value another chance to do the things he enjoyed most?

A. HeartMate®
A New Beginning™

Jim, 70 years old, was diagnosed with ischemic cardiomyopathy, NYHA Class IV, LVEF was 15%, with MVO, of 10.2, and a history of recurrent hospitalizations and of long standing disability from heart failure due to multiple Mls. Post implant, Jim has been supported by the HeartMate VE LVAS for over three years and remains NYHA Class I. For Jim and other ESHF patients, the HeartMate Vented Electric (VE) LVAS has provided a new beginning.*

- Improved quality of life and increased survival rates
- The first left ventricular assist system approved by the FDA for the permanent treatment of end-stage heart failure*
- Rapid and extended improvement in NYHA classification
- From a world leader in products to treat cardiovascular disease

To find out more about the HeartMate XVE LVAS for Destination Therapy, visit www.destination-therapy.com or call +44 1480 461866.

* NYHA Class IV patients with end-stage left ventricular failure who have received optimal medical therapy for at least 60 of the last 90 days, who have a life expectancy of less than two years, and who are not candidates for cardiac transplantation.

Actual patient featured.
patients with proximal left-anterior coronary artery disease, PTCA did not reduce the incidence of death or MI compared with medical therapy.

Coronary artery bypass surgery utilises venous or arterial conduits and increases the blood flow to the areas distal to the significant stenotic lesions. The procedure is effective in patients with graftable vessels and abolishes or reduces angina frequency in 70% to 80% of patients. Angina-free exercise duration also increases following surgery. In unblinded, parallel-design, randomised studies, coronary bypass surgery reduced neither the incidence of death nor the frequency of MI compared with medical therapy. Subgroup, post hoc analysis showed that patients with severe narrowing of the left main coronary artery and those with poor left-ventricular function and multivessel coronary artery disease (MVD) had better survival rates after surgery compared with medical treatment. Recent trials have compared coronary bypass surgery to PTCA with or without stent placement. Both strategies are equally effective in relieving angina although the need for a repeat percutaneous procedure or bypass surgery is greater in patients who have undergone a percutaneous revascularisation procedure. Currently, bypass surgery is indicated in diabetic patients with MVD.

Many of the patients who have undergone bypass surgery experience recurrence of symptoms over time due to progressive atherosclerotic occlusion of the venous conduits. This usually manifests itself 10 to 15 years after surgery and, in many of these patients, native coronary arteries are not suitable for a repeat revascularisation procedure due to disease progression.

Given the evidence that neither percutaneous interventions nor coronary artery bypass surgery improves survival or reduces serious adverse outcomes compared with medical therapy, it is preferable to try medical therapy first and consider percutaneous intervention or bypass surgery if medical therapy has failed.

Enhanced external counterpulsation (EECP) improves exercise performance with reduction in myocardial ischaemia in patients with stable angina pectoris. However, reported trials are rather small and, at present, EECF is reserved for patients who do not respond to conventional anti-anginal therapy and are not candidates for a revascularisation procedure.

At present, direct laser revascularisation procedures are only being used in patients who are not candidates for a revascularisation procedure and are refractory to medical therapy. Percutaneous transmyocardial revascularisation is not superior to a sham procedure in patients with stable angina. Spinal cord stimulation and transcutaneous nerve stimulation are reserved for those patients who are not candidates for a revascularisation procedure and remain very symptomatic despite optimal drug therapy.

Anti-anginal drugs, PTCA with or without stents, bypass surgery and other devices do not improve survival or reduce the incidence of MI in patients with stable angina. The following strategies are, therefore, needed to improve outcome.

**Treatment Aimed at Reducing Adverse Outcomes**

Smoking cessation reduces the risk of coronary artery disease mortality by 50% after one year. After five to 10 years, the coronary mortality rate in ex-smokers matches that of non-smokers. Stopping smoking may increase exercise performance in patients with stable angina pectoris.

Aspirin reduces the incidence of death and acute MI in patients with stable angina pectoris. Therefore, all patients with stable angina pectoris should be treated with daily aspirin (81mg to 320mg), provided they do not have a history of allergic reaction to aspirin and do not experience intolerable gastrointestinal side effects.

There is no data to indicate that newer antiplatelet agents – clopidogrel and ticlopidine – are superior to aspirin in patients with stable angina pectoris. Large-scale trials comparing aspirin with clopidogrel in patients with stable angina pectoris are lacking.

Lipid lowering therapy, especially with statins, reduces coronary morbidity and mortality in patients with established coronary artery disease. In a small study, aggressive lowering of low-density lipoprotein cholesterol with atorvastatin plus anti-anginal therapy was superior to percutaneous interventions plus anti-anginal therapy in patients with stable angina pectoris. Gemfibrozil reduced the incidence of serious adverse outcome in male patients with stable angina and low high-density lipoprotein levels (<35mg per dl) in the Veterans’ Administration Low High-density Lipoprotein Cholesterol Intervention Trial (VA-HIT).

Available data supports the aggressive treatment of lipid abnormalities in addition to daily use of aspirin and smoking cessation in patients with stable angina pectoris.
The clinical proof...

The CYPHER™ Stent:
• Proven in the greatest number of clinical trials with the greatest number of patients over the longest period of time. 1-4
• Proven to significantly reduce late loss, restenosis and target lesion revascularisation (TLR). 1-3
• Proven in a broad range of patients and lesions. 1-4
• Proven controlled-release, drug-elution technology now available with the improved flexibility and conformability of the CYPHER Select™ Stent.

Need more proof?
See for yourself...

...and the living proof

Now more easily delivered

CYPHER Select™ Stent
Sirolimus-eluting Coronary Stent

Make your first intervention last


CYPHER Select™ Stent is not for sale in the USA. This publication is not intended for distribution in the USA. Sirolimus-eluting Stent made by Cordis pursuant to a license from Wyeth Pharmaceuticals.